Rate Video

ESMO 2022 | Immunotherapy for sarcoma

Erlinda Gordon • 9 Oct 2022

Immuno-Oncology

Erlinda Gordon, MD, Cancer Center of Southern California/Sarcoma Oncology Center, Santa Monica, CA, discusses the use of immotherapy for sarcoma. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Cost and immune-related adverse events in patients with sarcoma treated with immunotherapy

Erlinda Gordon • 9 Sep 2022

Predictive biomarkers of response to immunotherapy in soft tissue sarcoma

Erlinda Gordon • 9 Sep 2022

Results of a Phase I/II study of ipi, nivo and trabectedin as 1L therapy for advanced LMS

Erlinda Gordon • 9 Sep 2022

Rationale of using immunotherapy for advanced leiomyosarcoma

Erlinda Gordon • 9 Sep 2022

Related Videos

Trabectedin and pazopanib: an indirect comparison of their ability to treat LMS

How has the trabectedin extended access program benefited sarcoma patients?

The current state of drug development against sarcomas

Response rates to immunotherapy in sarcoma patients and implications for future therapies

Gary Schwartz • 3 Jun 2016